UPA IUS

Product Overview

Alternative Name: Ulipristal acetate (UPA) Intrauterine System (IUS)

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Intrauterine

Duration Type: Long-acting

Description: UPA is a selective progesterone receptor modulator, released via an intrauterine system.

Updated date: May 30, 2018

Vertical Tabs

Product Details

Active Pharmaceutical Ingredient (API): ulipristal acetate

Inactive material: Elastomer

Potential Multi-Purpose Technology (MPT): No

Duration: 3 years

Partner: HRA Pharma, Population Council

Status

Project Phase: Early Development

Project Stage: Pre-clinical

Began discovery in: 2013

Status Details:
Prototypes are being designed and developed first for a preclinical toxicology study. This will be followed by development of GMP material for a first proof-of concept clinical trial.

Programmatic Considerations

Considerations:
Targets are to improve the existing IUD by suppressing the monthly heavy bleeding and obtaining amenorrhea. It will reduce irregular bleeding in the first year.

Additional Information

Additional Information:
HRA Pharma website: http://www.hra-pharma.com/

Brenner RM, Slayden OD, et al. (2010) Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception. 81(4):336-42.

Download Product Report

Alternative Name: Ulipristal acetate (UPA) Intrauterine System (IUS)

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Intrauterine

Duration Type: Long-acting

Description: UPA is a selective progesterone receptor modulator, released via an intrauterine system.

Updated date: May 30, 2018

Vertical Tabs

Active Pharmaceutical Ingredient (API): ulipristal acetate

Inactive material: Elastomer

Potential Multi-Purpose Technology (MPT): No

Duration: 3 years

Partner: HRA Pharma, Population Council

Project Phase: Early Development

Project Stage: Pre-clinical

Began discovery in: 2013

Status Details: Prototypes are being designed and developed first for a preclinical toxicology study. This will be followed by development of GMP material for a first proof-of concept clinical trial.

Considerations: Targets are to improve the existing IUD by suppressing the monthly heavy bleeding and obtaining amenorrhea. It will reduce irregular bleeding in the first year.

Additional Information: HRA Pharma website: http://www.hra-pharma.com/ Brenner RM, Slayden OD, et al. (2010) Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception. 81(4):336-42.

Status Details:
Prototypes are being designed and developed first for a preclinical toxicology study. This will be followed by development of GMP material for a first proof-of concept clinical trial.

Considerations:
Targets are to improve the existing IUD by suppressing the monthly heavy bleeding and obtaining amenorrhea. It will reduce irregular bleeding in the first year.

Additional Information:
HRA Pharma website: http://www.hra-pharma.com/

Brenner RM, Slayden OD, et al. (2010) Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception. 81(4):336-42.